Is It Just Muscle Weakness – When to Suspect and How to Diagnose Pompe Disease in the Era of Increased Treatment Options
April 26, 2023
April 26, 2024
This activity is jointly provided by P2P Syncro and Postgraduate Institute for Medicine.
This activity is supported by an independent educational grant from Sanofi.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 Contact Hour
- Physician Assistants — 1.0 CE Credit
- Pharmacists — 1.0 Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation.
Healthcare providers in pediatrics, internal medicine, family medicine, neurology, neuromuscular disease, pulmonology, radiology, and physical therapy.
In the past 2 years, 6.5 million Americans visited healthcare providers for muscle weakness, a presentation also occurs most frequently in those with Pompe disease. When to test for and how to diagnose Pompe disease among those with muscle weakness are the focus of discussion in this CME program.
Upon completion of this activity, participants should be able to:
- Assess phenotypes, presentations, and muscles affected in Pompe disease
- Evaluate the differential diagnosis of limb-girdle muscle weakness and Pompe disease
- Discuss when and how to test for Pompe disease in those with muscle weakness
Tahseen Mozaffar, MD
Dr. Mozaffar is a neurologist and professor at the University of California, Irvine. He is an internationally recognized expert in neuromuscular disease. Dr. Mozaffar has published extensively on various topics of Pompe disease. He led the effort and developed a consensus driven diagnostic algorithm. He is a senior investigator of a pivotal clinical trial on a novel therapy for Pompe disease
Jordi Diaz Manera, MD PhD
Dr. Diaz Manera is a neurologist and professor of neuromuscular disorders at Newcastle University in UK. He has authored over 160 peer-reviewed articles on topics including muscular dystrophies and quantitative muscle MRI. He is the lead investigator of a phase 3 clinical trial on Pompe disease and is instrumental in bringing new treatment to the patients suffering from the disease.
Physician Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and P2P Syncro. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour.
Pharmacy Continuing Education
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-23-107-H01-P. Type of Activity: Knowledge.)
Physician Assistant Continuing Education
Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until Jan 10, 2024. PAs should only claim credit commensurate with the extent of their participation.
Disclosures of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
- Tahseen Mozaffar, MD
- Consulting: Alexion, Amicus, Argenx, Arvinas, Audentes, AvroBio, Maze Therapeutics, Momenta/Janssen, Sanofi Genzyme, Sarepta, Spark Therapeutics, UCB/Ra Pharmaceuticals, and Modis/Zogenix
- Research support: Alexion, Amicus, Argenx, Arvinas, Audentes/Astellas Gene Therapy, Bristol-Myers-Squib, Cartesian Therapeutics, Grifols, Momenta, Ra Pharmaceuticals, Sanofi-Genzyme, Spark Therapeutics, UCB, and Valerion
- Speaker Bureau: Sanofi-Genzyme
- Jordi Diaz Manera, MD PhD
- Consulting: : Amicus, Audentes, Maze Therapeutics, Sanofi Genzyme, Sarepta, Spark Therapeutics
- Research support: Boehringer-Ingelheim, Sanofi, Spark and Sarepta
- Speaker Bureau: Sanofi-Genzyme, Sarepta, Lupin
The PIM planners and others have nothing to disclose. The P2P Syncro planners and others have nothing to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
Postgraduate Institute for Medicine (PIM) requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions please contact: [email protected].